ATS Urges Prioritizing AHD/AIDS and TB Treatment in Unitaid’s 2022-2026 Investment
The American Thoracic Society joined a letter to Unitaid’s Executive Board recommending greater attention to the drivers of readily preventable AIDS and tuberculosis deaths in Unitaid’s current Investment Plan and Strategic Framework for 2022-2026. The signatories ask that the Board prioritize measures needed most for preventing deaths from AHD/AIDS and for anticipating and addressing access barriers to long sought-after shorter, safer treatment regimens for TB. Unitaid is an innovative financing mechanism that raises new funds for global health and complements existing initiatives targeting HIV/AIDS, TB, and malaria. Unitaid funds endTB, which aims to find shorter, less toxic, and more effective treatments for multi-drug resistant TB.
